Status:
RECRUITING
Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV
Lead Sponsor:
Centre Hospitalier Universitaire de la Réunion
Conditions:
HPV Infection
Eligibility:
All Genders
30+ years
Phase:
NA
Brief Summary
Anal canal cancers are on the increase in France, with around 2,000 new cases per year. These lesions can be detected by directed biopsies or smear tests. The incidence rate of anal cancer is 30 time...
Eligibility Criteria
Inclusion
- Patient :
- living with HIV
- aged 30 or over
- resident on Reunion island and followed at the University Hospital of Reunion Island (the only follow-up center on the island)
- Able to perform anal self-sampling
- Able to answer a questionnaire
- Affiliated with or benefiting from a social security scheme
- Have given free, informed and signed consent
Exclusion
- People with a previous anal swab less than 7 days old
- Persons with a known current diagnosis of anal cancer
- Persons deprived of liberty by judicial or administrative decision, minors, and persons under legal protection: guardianship or curators
Key Trial Info
Start Date :
November 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 2 2027
Estimated Enrollment :
398 Patients enrolled
Trial Details
Trial ID
NCT06507917
Start Date
November 28 2025
End Date
January 2 2027
Last Update
December 11 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de la Réunion Recherche Clinique
Saint-Denis, Reunion, 97400
2
CHU de la Réunion Recherche Clinique
Saint-Pierre, Reunion, 97448